Editorial commentary: Universal antiretroviral therapy for HIV infection?

Clinical Infectious Diseases

Volumn 57, Issue 6, 2013, Pages 888-890

  Lundgren, Jens D ^a   Wood, Robin ^b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

antiviral therapy; risk benefit ratio; when to start

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; TENOFOVIR;

ADVERSE OUTCOME; ANTIVIRAL THERAPY; BEHAVIOR CHANGE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); EPIDEMIC; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; KIDNEY DISEASE; MEN WHO HAVE SEX WITH MEN; NOTE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSAFE SEX; VIRUS LOAD; VIRUS RESISTANCE; WORLD HEALTH ORGANIZATION;

ANTIVIRAL THERAPY; RISK-BENEFIT RATIO; WHEN TO START;

ANTI-RETROVIRAL AGENTS; GUIDELINE ADHERENCE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; QUALITY ASSURANCE, HEALTH CARE;

EID: 84883208838     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit381     Document Type: Note

References (22)

1. Cohen MS, Chen YQ, McCauley M, et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
2. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
3. Lundgren JD, Babiker AG, Gordin FM, Borges AH, Neaton JD. When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Med 2013. In press.
4. Sabin CA, Cooper DA, Collins S, Schechter M. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIVpositive asymptomatic persons. AIDS 2013 [Epub ahead of print]. doi:10.1097/QAD. 0b013e328360d546.
5. Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC; 2013. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 12 February 2013.
6. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
7. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13(suppl 2):1-85.
8. European AIDS Clinical Society. European guidelines for treatment ofHIV infected adults in Europe. 2012. Available at: http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6. 1-2edition.pdf. Accessed November 2012.
9. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2010 revision. Geneva, Switzerland; 2010. Available at: http://whqlibdoc. who.int/publications/2010/9789241599764-eng.pdf. Accessed 2010.
10. El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral therapy. N Engl J Med 2006; 355: 2283-96.
11. Gallant JE, Mehta SH, Sugerman J. Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? Clin Infect Dis 2013; 57:884-7.
12. Bedimo R, Maalouf NM, Zhang S, Drechsler HTebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012; 26:825-31.
13. Ryom L, Mocroft A, Kirk O, et al. on behalf of the D:A:D Study Group. Exposure to antiretrovirals (ARVs) and risk of renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D Study. J Infect Dis 2013; 207:1359-69.
14. Pujari S, Smith C, Makane A, Youle M, Johnson M, Bhagani S. Tenofovir is associated with an increased risk and faster progression of renal impairment amongst HIV+ patients. CROI, 2013. Available at: http://www. retroconference.org/2013b/Abstracts/47068.htm. Accessed 6 March 2013.
15. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 2011; 25:843-50.
16. Babiker AG, Emery S, Fätkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of Anti-Retroviral Treatment (START) study. Clin Trials 2013; 10(1 suppl):S5-36.
17. De Cock KM, El-SadrW. When to start ART in Africa-an urgent research priority. N Engl J Med. 2013; 368:886-9.
18. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-30.
19. Chao C, Leyden WA, Xu L, et al. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS 2012; 26: 2223-31.
20. Scourfield A, Zheng J, Chinthapalli S, et al. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS 2012; 26:1399-401.
21. Kitahata MM, Gange SJ, Abraham AG, et al.; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl JMed 2009; 360:1815-26.
22. Phillips AN, Cambiano V, Nakagawa F, et al. Increased HIV incidence in men who have sex with men despite high levels of ARTinduced viral suppression: analysis of an extensively documented epidemic [Epub ahead of print]. PLoS One 2013; doi:10.1371/journal.pone.0055312.